Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease
- 1 August 2017
- journal article
- review article
- Published by Elsevier BV in Kidney International
- Vol. 92 (2), 306-312
- https://doi.org/10.1016/j.kint.2017.02.035
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesisJCI Insight, 2012
- Renal Tubular HIF-2α Expression Requires VHL Inactivation and Causes Fibrosis and CystsPLOS ONE, 2012
- Inhibition of HIF Prolyl Hydroxylase-2 Blocks Tumor Growth in Mice through the Antiproliferative Activity of TGFβCancer Research, 2011
- Donor treatment with a PHD-inhibitor activating HIFs prevents graft injury and prolongs survival in an allogenic kidney transplant modelProceedings of the National Academy of Sciences of the United States of America, 2009
- Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2α mutationBlood, 2008
- Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failureBlood, 2008
- A Gain-of-Function Mutation in theHIF2AGene in Familial ErythrocytosisThe New England Journal of Medicine, 2008
- Acute postnatal ablation of Hif-2 α results in anemiaProceedings of the National Academy of Sciences of the United States of America, 2007
- Correction of Anemia with Epoetin Alfa in Chronic Kidney DiseaseThe New England Journal of Medicine, 2006
- Disruption of oxygen homeostasis underlies congenital Chuvash polycythemiaNature Genetics, 2002